Seong Hayoung, Kim Soo Han, Kim Mi Hyun, Cho Jeong Su, Kim Ahrong, Eom Jung Seop
Department of Internal Medicine, Pusan National University School of Medicine, Busan, Republic of Korea.
Department of Internal Medicine, Pusan National University Hospital, Busan, Republic of Korea.
Front Oncol. 2024 Jul 11;14:1343238. doi: 10.3389/fonc.2024.1343238. eCollection 2024.
The use of neoadjuvant anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitors (TKIs) has not been extensively explored. The current case report highlights the notable pathological complete response (pCR) achieved following neoadjuvant brigatinib therapy in a patient with stage IIIA ALK-positive non-small cell lung cancer (NSCLC).
A 32-year-old male presented with incidental lung lesions, ultimately diagnosed as clinical stage T3N1M0, IIIA NSCLC with an gene rearrangement. Following a multidisciplinary discussion, the patient opted for neoadjuvant brigatinib therapy, which significantly reduced the tumor size. Subsequently, surgery with curative intent was performed, revealing pCR with no residual tumor cells. The patient remained disease-free during a 13-month follow-up period.
This case report provides compelling evidence of pCR following brigatinib therapy in ALK-positive NSCLC, suggesting that surgery after neoadjuvant therapy with brigatinib may offer a safe and effective approach for patients with ALK-positive NSCLC.
新辅助间变性淋巴瘤激酶（ALK）-酪氨酸激酶抑制剂（TKIs）的应用尚未得到广泛研究。本病例报告强调了一名IIIA期ALK阳性非小细胞肺癌（NSCLC）患者在接受新辅助布加替尼治疗后取得的显著病理完全缓解（pCR）。
一名32岁男性因偶然发现肺部病变就诊，最终诊断为临床分期T3N1M0、IIIA期NSCLC且存在 基因重排。经过多学科讨论，患者选择新辅助布加替尼治疗，该治疗显著缩小了肿瘤大小。随后进行了根治性手术，结果显示为pCR，无残留肿瘤细胞。在13个月的随访期内，患者无疾病复发。
本病例报告提供了布加替尼治疗ALK阳性NSCLC后出现pCR的有力证据，表明布加替尼新辅助治疗后手术可能为ALK阳性NSCLC患者提供一种安全有效的治疗方法。
